Carotuximab
- Generic Name
- Carotuximab
- Drug Type
- Biotech
- CAS Number
- 1268714-50-6
- Unique Ingredient Identifier
- YB2EWE6139
- Indication
Investigated for use/treatment in solid tumors.
TRC105 for Recurrent Glioblastoma
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT01778530
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
- Conditions
- Glioblastoma MultiformeGlioblastoma
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Tracon Pharmaceuticals Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01564914
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
- Conditions
- Hepatocellular CarcinomaHepatocellular CancerCarcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT01375569
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
- Conditions
- Urothelial CarcinomaUreteral NeoplasmsUreter CancerNeoplasm, UreteralCancer of the Ureter
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT01328574
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
- First Posted Date
- 2011-03-31
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Tracon Pharmaceuticals Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01326481
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Sorafenib and TRC105 in Hepatocellular Cancer
- Conditions
- Carcinoma, HepatocellularLiver NeoplasmsAdenoma, Liver CellHepatomaLiver Neoplasms, Experimental
- Interventions
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT01306058
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
- Conditions
- Metastatic Castrate Resistant Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT01090765
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.